Medpace and Iqvia stocks surged Tuesday after the duo kicked off earnings season with unexpectedly strong reports.

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today ...

Q2 2025 Earnings Call Transcript July 22, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $2.81, ...

IQVIA Holdings stock surged on Tuesday after the clinical research and analytics company's second-quarter results topped ...

Clinical research company IQVIA (NYSE: IQV) reported Q2 CY2025 results topping the market’s revenue expectations, with sales ...

In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the concerns and opportunities of ...

IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into ...

Analysts have given IQVIA Hldgs a total of 7 ratings, with the consensus rating being Neutral. The average one-year price target is $174.0, indicating a potential 8.32% upside.

IQVIA reports record $4B+ revenue in Q2 2025, driven by TAS & AI initiatives. Explore robust growth, R&D momentum, and strategic partnerships.

Contract research firm IQVIA Holdings posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares ...

IQVIA Holdings Inc.'s Q1 results highlighted strong profitability, robust TAS growth, and a healthy backlog. Click here to read an analysis of IQV stock now.

Contacts IQVIA Investor Relations Andrew Markwick, +1-973-257-7144 andrew.markwick@iqvia.com or IQVIA Media Relations Tor Constantino, +1-484-567-6732 tor.constantino@iqvia.com ...